This article is more than 5 years old. Information may no longer be current.

Seven important updates from European Society for Medical Oncology Congress

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

This year’s European Society for Medical Oncology Congress, held Sept. 8-12 in Madrid, featured the theme, “Integrating science into oncology for a better patient outcome.”

HemOnc Today presents seven important studies you may have missed from the ESMO Congress.

• Adjuvant treatment with nivolumab (Opdivo, Bristol-Myers Squibb) significantly prolonged RFS compared with standard ipilimumab (Yervoy, Bristol-Myers Squibb) for patients with surgically resected stage III or stage IV melanoma at high risk for recurrence, according to results of the randomized, phase 3 CheckMate 238 trial. Read more. Read perspective from Omid Hamid, MD.
• Nearly one-quarter of women with small breast cancers are at risk for distant metastases and may derive benefit from adjuvant chemotherapy, according to a substudy of the MINDACT trial. Read more. Read perspective from Hope S. Rugo, MD.
• The addition of abemaciclib (LY2835219, Eli Lilly) to endocrine therapy extended PFS and improved response rates among postmenopausal women with hormone receptor-positive, HER-2-negative advanced breast cancer. Read more. Read perspective from Nicholas Turner, MA, MRCP, PhD.
• The immunotherapy combination of nivolumab plus ipilimumab improved objective response rate and prolonged PFS compared with sunitinib in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma. Read more. Read perspective from Manuela Schmidinger, MD.
• The addition of ramucirumab (Cyramza, Eli Lilly) to docetaxel conferred a small but statistically significant PFS benefit for patients with advanced or metastatic urothelial cancer whose disease progressed on platinum-based chemotherapy. Read more. Read perspective from Yohann Loriot, MD.
• Neoadjuvant chemotherapy followed by radical surgery did not improve outcomes compared with cisplatin-based concurrent chemoradiation for women with locally advanced squamous carcinoma of the cervix. Read more. Read perspective from Domenica Lorusso, MD, PhD.
• Adjuvant treatment with imatinib improved outcomes among patients with high-risk gastrointestinal stromal tumors. Read more. Read perspective from Sebastian Bauer, MD.